Blog Anti-Diabetes Therapies and Bone Safety May 28, 2013 Recent information indicates that 50% of elderly individuals in the US are osteoporotic and almost 20% of the population is either diabetic or prediabetic. Reduction Apr 23, 2013 It Sounds like a Great Idea, but how do we Apply “Reduction” to Toxicology Studies? Cutting-edge Preclinical QT Assessment Reduces Late-stage Drug Failures Mar 26, 2013 The clinical effects of drugs on cardiac repolarization and rhythm, particularly the induction of potentially fatal arrhythmias have been increasingly documented over the past two decades. NORD Explores the Economic Costs of Rare Disorders Dec 17, 2012 Together, there are nearly 7,000 orphan diseases that impact nearly 30 million Americans who NORD supports through education, research, and advocacy. Orphan Drugs or Personalized Medicine? Dec 05, 2012 With the continued development of drugs for specific diseases, disease populations and disease mechanisms, will the strategies applied to orphan drug development benefit the development of personalized medicines? Abandon the Amyloid Hypothesis? New Research Says Not So Fast Nov 26, 2012 After the recent failures of two Alzheimer’s drugs that target amyloid beta plaques, many have questioned the approach. But new data released in October shows promise. Treatment Advances for Acute Lymphoblastic Leukemia Increase Survival Rates Oct 01, 2012 Mortality rates for this most common childhood cancer are dropping due to remarkable advances in diagnosis and treatment. Charles River’s Shawna M. Jackman Offers Tips for Translational Stem Cell Therapy Research May 22, 2012 Check out Charles River Senior Research Scientist Shawna M. Jackman’s recent post to GEN’s blog, 10 Tips for Translational Stem Cell Therapy Research. Susan Y. Smith featured in Genetic Engineering & Biotechnology News May 15, 2012 Charles River Senior Scientific Director Susan Y. Smith discussed the skeleton’s function in human physiology in Emerging Insights into the Role of the Skeleton, featured in a recent edition of GEN. Former FDA Reviewer Discusses Agency’s Recommendations for Biosimilar Development Mar 06, 2012 On February 9th, 2012, the FDA published recommendations for the development of biosimilars. For 60 days, these draft guidance documents will be open for comments and questions. Displaying results 1-10 (of 11) |< < 1 - 2 > >|
Anti-Diabetes Therapies and Bone Safety May 28, 2013 Recent information indicates that 50% of elderly individuals in the US are osteoporotic and almost 20% of the population is either diabetic or prediabetic.
Reduction Apr 23, 2013 It Sounds like a Great Idea, but how do we Apply “Reduction” to Toxicology Studies?
Cutting-edge Preclinical QT Assessment Reduces Late-stage Drug Failures Mar 26, 2013 The clinical effects of drugs on cardiac repolarization and rhythm, particularly the induction of potentially fatal arrhythmias have been increasingly documented over the past two decades.
NORD Explores the Economic Costs of Rare Disorders Dec 17, 2012 Together, there are nearly 7,000 orphan diseases that impact nearly 30 million Americans who NORD supports through education, research, and advocacy.
Orphan Drugs or Personalized Medicine? Dec 05, 2012 With the continued development of drugs for specific diseases, disease populations and disease mechanisms, will the strategies applied to orphan drug development benefit the development of personalized medicines?
Abandon the Amyloid Hypothesis? New Research Says Not So Fast Nov 26, 2012 After the recent failures of two Alzheimer’s drugs that target amyloid beta plaques, many have questioned the approach. But new data released in October shows promise.
Treatment Advances for Acute Lymphoblastic Leukemia Increase Survival Rates Oct 01, 2012 Mortality rates for this most common childhood cancer are dropping due to remarkable advances in diagnosis and treatment.
Charles River’s Shawna M. Jackman Offers Tips for Translational Stem Cell Therapy Research May 22, 2012 Check out Charles River Senior Research Scientist Shawna M. Jackman’s recent post to GEN’s blog, 10 Tips for Translational Stem Cell Therapy Research.
Susan Y. Smith featured in Genetic Engineering & Biotechnology News May 15, 2012 Charles River Senior Scientific Director Susan Y. Smith discussed the skeleton’s function in human physiology in Emerging Insights into the Role of the Skeleton, featured in a recent edition of GEN.
Former FDA Reviewer Discusses Agency’s Recommendations for Biosimilar Development Mar 06, 2012 On February 9th, 2012, the FDA published recommendations for the development of biosimilars. For 60 days, these draft guidance documents will be open for comments and questions.
